AR051713A1 - Derivado de pirrol sustituido - Google Patents

Derivado de pirrol sustituido

Info

Publication number
AR051713A1
AR051713A1 ARP050105189A ARP050105189A AR051713A1 AR 051713 A1 AR051713 A1 AR 051713A1 AR P050105189 A ARP050105189 A AR P050105189A AR P050105189 A ARP050105189 A AR P050105189A AR 051713 A1 AR051713 A1 AR 051713A1
Authority
AR
Argentina
Prior art keywords
group
optionally substituted
atom
substituted
optionally
Prior art date
Application number
ARP050105189A
Other languages
English (en)
Inventor
N Matsunaga
M Ito
T Hitaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR051713A1 publication Critical patent/AR051713A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente proporciona un nuevo derivado de pirrol que tiene un excelente antagonismo de los receptores de androgenos, el cual está representado por la formula (1) en donde R1 representa un átomo de H, un grupo ciano o un grupo representado por la formula COORA (en donde RA representa un grupo alquilo C1-6 opcionalmente sustituido, R2 y R4 son iguales o diferentes, y cada uno representa un átomo de H, un grupo alquilo C1-6, un grupo cicloalquilo C3-6, un grupo trifluorometilo, un grupo aminoalquilo C1-6, un grupo aminoalquilo C1-6 mono- o disustituido, un grupo alquilo C1-6 opcionalmente halogenado sustituido con un grupo hidroxilo opcionalmente sustituido, un grupo alquenilo C2-6 ustituido con un grupo hidroxilo opcionalmente sustituido, un grupo alquilo C1-6 sustituido con un grupo tiol opcionalmente sustituido y opcionalmente oxidado, un grupo tiol opcionalmente sustituido y opcionalmente oxidado, un grupo ciano, un grupo acilo, un grupo oxazolilo opcionalmente sustituido o un grupo 1,3-dioxolan-2-ilo; R3 representa un grupo representado por la formula (2) (en donde X representa un átomo de halogeno, Y representa un átomo de C o un átomo de N, Alk representa un grupo alquileno C1-4 opcionalmente sustituido, y RB representa un átomo de H o un grupo acilo), y R5 representa un grupo fenilo que tiene un grupo ciano en la posicion 4 o en la posicion 3, y también puede estar sustituido, o una de sus sales. LA presente también proporciona un antagonista del receptor de androgenos que contiene el derivado pirrol, o una de sus sales.
ARP050105189A 2004-12-14 2005-12-12 Derivado de pirrol sustituido AR051713A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004361641 2004-12-14

Publications (1)

Publication Number Publication Date
AR051713A1 true AR051713A1 (es) 2007-01-31

Family

ID=35883518

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105189A AR051713A1 (es) 2004-12-14 2005-12-12 Derivado de pirrol sustituido

Country Status (7)

Country Link
US (1) US20080176906A1 (es)
EP (1) EP1824841A1 (es)
JP (1) JP2008523052A (es)
AR (1) AR051713A1 (es)
PE (1) PE20060734A1 (es)
TW (1) TW200628446A (es)
WO (1) WO2006064944A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172559A1 (en) 2007-06-13 2010-04-07 Takeda Pharmaceutical Company Limited Screening method
GB0711776D0 (en) * 2007-06-18 2007-07-25 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
EA201070323A1 (ru) * 2007-08-30 2010-10-29 Такеда Фармасьютикал Компани Лимитед Замещенное производное пиразола
CN104188971B (zh) 2007-12-21 2017-05-03 配体药物公司 选择性雄激素受体调节剂(sarm)及其应用
US20090270361A1 (en) * 2008-03-26 2009-10-29 Takeda Pharmaceutical Company Limited Substituted pyrazole derivatives and use thereof
EP3241826B1 (en) 2009-02-25 2019-10-30 Takeda Pharmaceutical Company Limited Process for producing pyrrole compound
EA201390598A1 (ru) 2010-10-22 2013-08-30 Астеллас Фарма Инк. Антагонист мутантного андрогенного рецептора
CA2970565A1 (en) * 2014-12-15 2016-06-23 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies
CN105218437A (zh) * 2015-10-31 2016-01-06 高大元 一种3-氯-5-溴-2-吡啶甲酸的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
GB0016453D0 (en) * 2000-07-04 2000-08-23 Hoffmann La Roche Pyrrole derivatives
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
WO2003057669A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Antagonistes du recepteur androgene
SI1557411T1 (es) * 2002-07-12 2013-01-31 Astellas Pharma Inc
JP2006515605A (ja) * 2003-01-17 2006-06-01 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アンドロゲンレセプターアンタゴニスト

Also Published As

Publication number Publication date
JP2008523052A (ja) 2008-07-03
WO2006064944A1 (en) 2006-06-22
TW200628446A (en) 2006-08-16
US20080176906A1 (en) 2008-07-24
EP1824841A1 (en) 2007-08-29
PE20060734A1 (es) 2006-09-05

Similar Documents

Publication Publication Date Title
AR051713A1 (es) Derivado de pirrol sustituido
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
CO5631436A2 (es) Amidas y acidos derivados del bencimidazol para el tratamiento del dolor y la inflamacion
AR084588A1 (es) Compuesto heterociclico fusionado y su uso para el control de plagas
AR054529A1 (es) Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6
AR057987A1 (es) Compuestos agonistas de cb1 (receptor cannabinoide)
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR080074A1 (es) Naftiridinas sustituidas y su uso como medicamentos
AR047456A1 (es) Derivados de amidas, procesos para su preparacion y uso como insecticidas
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR060590A1 (es) Compuestos imidazo
AR058776A1 (es) Compuesto de piridina condensado
CO6251247A2 (es) Imidazoquinolinas con propiedades inmuno-moduladoras
AR073774A1 (es) Compuestos antibioticos oxazolidinona triciclicos
AR013693A1 (es) Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
AR060635A1 (es) Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR058006A1 (es) Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos
AR053725A1 (es) Compuestos triciclicos de base 1,6-dihidro-1,3,5,6-tetraaza-as-indaceno y composiciones farmaceuticas que comprenden los mismos
CO6251271A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
AR060605A1 (es) Derivados de diazepano como antagonistas del receptor ccr2
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR050143A1 (es) Combinacion de herbicidas y antidotos
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal